Sharma Ramaish, Khan Zuber, Mehan Sidharth, Das Gupta Ghanshyam, Narula Acharan S
Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University, Jalandhar, Punjab 144603, India.
Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University, Jalandhar, Punjab 144603, India.
Mutat Res Rev Mutat Res. 2024 Jul-Dec;794:108518. doi: 10.1016/j.mrrev.2024.108518. Epub 2024 Nov 2.
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, primarily impairs upper and lower motor neurons, leading to debilitating motor dysfunction and eventually respiratory failure, widely known as Lou Gehrig's disease. ALS presents with diverse symptomatology, including dysarthria, dysphagia, muscle atrophy, and hyperreflexia. The prevalence of ALS varies globally, with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45-80. A complex interplay of genetic and environmental factors underpins ALS pathogenesis. Key genetic contributors include mutations in chromosome 9 open reading frame 72 (C9ORF72), superoxide dismutase type 1 (SOD1), Fusedin sarcoma (FUS), and TAR DNA-binding protein (TARDBP) genes, accounting for a considerable fraction of both familial (fALS) and sporadic (sALS) cases. The disease mechanism encompasses aberrant protein folding, mitochondrial dysfunction, oxidative stress, excitotoxicity, and neuroinflammation, contributing to neuronal death. This review consolidates current insights into ALS's multifaceted etiology, highlighting the roles of environmental exposures (e.g., toxins, heavy metals) and their interaction with genetic predispositions. We emphasize the polygenic nature of ALS, where multiple genetic variations cumulatively influence disease susceptibility and progression. This aspect underscores the challenges in ALS diagnosis, which currently lacks specific biomarkers and relies on symptomatology and familial history. Therapeutic strategies for ALS, still in nascent stages, involve symptomatic management and experimental approaches targeting molecular pathways implicated in ALS pathology. Gene therapy, focusing on specific ALS mutations, and stem cell therapy emerge as promising avenues. However, effective treatments remain elusive, necessitating a deeper understanding of ALS's genetic architecture and the development of targeted therapies based on personalized medicine principles. This review aims to provide a comprehensive understanding of ALS, encouraging further research into its complex genetic underpinnings and the development of innovative, effective treatment modalities.
肌萎缩侧索硬化症(ALS)是一种进行性神经退行性疾病,主要损害上下运动神经元,导致使人衰弱的运动功能障碍,最终引发呼吸衰竭,该病广为人知,被称为卢伽雷氏病。ALS的症状表现多样,包括构音障碍、吞咽困难、肌肉萎缩和反射亢进。ALS在全球的患病率各不相同,发病率为每10万人中有1.5至3.8人,对45至80岁的人群影响尤为显著。遗传因素和环境因素的复杂相互作用是ALS发病机制的基础。关键的遗传因素包括9号染色体开放阅读框72(C9ORF72)、超氧化物歧化酶1(SOD1)、融合肉瘤(FUS)和TAR DNA结合蛋白(TARDBP)基因的突变,在家族性(fALS)和散发性(sALS)病例中都占了相当比例。疾病机制包括异常蛋白质折叠、线粒体功能障碍、氧化应激、兴奋性毒性和神经炎症,这些都会导致神经元死亡。本综述整合了目前对ALS多方面病因的见解,强调了环境暴露(如毒素、重金属)的作用及其与遗传易感性的相互作用。我们强调ALS的多基因性质,即多个基因变异会累积影响疾病易感性和进展。这一点凸显了ALS诊断的挑战,目前缺乏特异性生物标志物,主要依靠症状和家族病史进行诊断。ALS的治疗策略仍处于初期阶段,包括对症治疗以及针对ALS病理相关分子途径的实验性方法。针对特定ALS突变的基因治疗和干细胞治疗是很有前景的途径。然而,有效的治疗方法仍然难以捉摸,这就需要更深入地了解ALS的遗传结构,并根据个性化医疗原则开发靶向治疗方法。本综述旨在全面介绍ALS,鼓励对其复杂的遗传基础进行进一步研究,并开发创新、有效的治疗方式。